ArticleParasites & vectors2019
Ellagic acid microspheres restrict the growth of Babesia and Theileria in vitro and Babesia microti in vivo.
Article in Parasites & vectors, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 51 citations in OpenAlex.
- Recent advancements in phytotherapeutics for controlling babesiosis and theileriosis.Tropical animal health and production · 2026Review
- Potential effect of cerium oxide nanoparticles against boldenone-induced oxidative stress, inflammation, and reproductive dysfunction in male albino rats.Scientific reports · 2026Article
- Natural products against Babesiosis: active compounds, molecular mechanisms, application limitations and translational development.Frontiers in cellular and infection microbiology · 2026Review
- Ellagic Acid fromMolecules (Basel, Switzerland) · 2025Article
- Bioactive Compounds from Plant Origin as Natural Antimicrobial Agents for the Treatment of Wound Infections.International journal of molecular sciences · 2024Review
- Recent Advances in Potential Health Benefits of Quercetin.Pharmaceuticals (Basel, Switzerland) · 2023Review
- The Antimicrobial Applications of Nanoparticles in Veterinary Medicine: A Comprehensive Review.Antibiotics (Basel, Switzerland) · 2023Review
- Ethnobotany, phytochemistry and pharmacological properties of Fagopyri Dibotryis Rhizoma: A review.Frontiers in pharmacology · 2023Review
- Ellagic Acid: A Review on Its Natural Sources, Chemical Stability, and Therapeutic Potential.Oxidative medicine and cellular longevity · 2022Review
- Nutraceutical Profiling, Bioactive Composition, and Biological Applications ofOxidative medicine and cellular longevity · 2022Review
- Treatment of Human Babesiosis: Then and Now.Pathogens (Basel, Switzerland) · 2021Review
- Ellagic Acid-Cyclodextrin Complexes for the Treatment of Oral Candidiasis.Molecules (Basel, Switzerland) · 2021Article
- Botanical Medicines Cryptolepis sanguinolenta, Artemisia annua, Scutellaria baicalensis, Polygonum cuspidatum, and Alchornea cordifolia Demonstrate Inhibitory Activity Against Babesia duncani.Frontiers in cellular and infection microbiology · 2021Article
- Twenty Years of Equine Piroplasmosis Research: Global Distribution, Molecular Diagnosis, and Phylogeny.Pathogens (Basel, Switzerland) · 2020Review
- Inhibitory effects of novel ciprofloxacin derivatives on the growth of four Babesia species and Theileria equi.Parasitology research · 2020Article
- Avermectin Derivatives, Pharmacokinetics, Therapeutic and Toxic Dosages, Mechanism of Action, and Their Biological Effects.Pharmaceuticals (Basel, Switzerland) · 2020Review
- In vitro and in vivo growth inhibitory activities of cryptolepine hydrate against several Babesia species and Theileria equi.PLoS neglected tropical diseases · 2020Article
- Chemo-Protective Potential of Cerium Oxide Nanoparticles against Fipronil-Induced Oxidative Stress, Apoptosis, Inflammation and Reproductive Dysfunction in Male White Albino Rats.Molecules (Basel, Switzerland) · 2020Article
- Assessing the Immunochromatographic Test Strip for Serological Detection of Bovine Babesiosis in Uganda.Microorganisms · 2020Article
- Biological Properties, Bioactive Constituents, and Pharmacokinetics of SomeInternational journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
Abstract
backgroundThere are no effective vaccines against Babesia and Theileria parasites; therefore, therapy depends heavily on antiprotozoal drugs. Treatment options for piroplasmosis are limited; thus, the need for new antiprotozoal agents is becoming increasingly urgent. Ellagic acid (EA) is a polyphenol found in various plant products and has antioxidant, antibacterial and effective antimalarial activity in vitro and in vivo without toxicity. The present study documents the efficacy of EA and EA-loaded nanoparticles (EA-NPs) on the growth of Babesia and Theileria.
methodsIn this study, the inhibitory effect of EA, β-cyclodextrin ellagic acid (β-CD EA) and antisolvent precipitation with a syringe pump prepared ellagic acid (APSP EA) was evaluated on four Babesia species and Theileria equi in vitro, and on the multiplication of B. microti in mice. The cytotoxicity assay was tested on Madin-Darby bovine kidney (MDBK), mouse embryonic fibroblast (NIH/3T3) and human foreskin fibroblast (HFF) cell lines.
resultsThe half-maximal inhibitory concentration (IC
conclusionsTo our knowledge, this is the first study to demonstrate the in vitro and in vivo antibabesial action of EA-NPs and thus supports the use of nanoparticles as an alternative antiparasitic agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.